THERAPY DOSSIER · th-09fe6654a5ca

Manganese superoxide dismutase gene-modified mesenchymal stem cells

Biologic

Evidence & regulatory context

Mechanism: Not recorded
Target: Not recorded
Injury models: Radiation
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 0

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

No linked human trial in this dataset.

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 27806643 ↗2016Reported benefit

Manganese Superoxide Dismutase Gene-Modified Mesenchymal Stem Cells Attenuate Acute Radiation-Induced Lung Injury.

MouseRadiationNonobese diabetic/severe combined immunodeficiency (NOD/SCID)maleIntravenous transfusionAfter whole-thorax irradiation, with monitoring for 30 days

Model: Whole-thorax irradiation with a 13 Gy dose

Systemic administration of MnSOD gene-modified mesenchymal stem cells attenuated lung inflammation, reduced lung damage and protected lung cells from apoptosis, with the cells differentiating into epithelial-like cells in vivo.

Extraction: extract · Supplied extraction confidence: 0.65. Machine-extracted fields require source verification.

Loading the evidence…